A Clinical Trial of Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects

Phase 1 Completed 6 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

To analyze radioactivity excretion and pharmacokinetics in healthy subjects after a single oral dose of \[¹⁴C\]TQ05105, identifying excretion routes, major metabolites, and biotransformation pathways. Secondary: To determine pharmacokinetics of TQ05105 and metabolites (e.g., TQ12550) via Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) and assess treatment safety.

Timeline

Start: 2024-03-18
Primary completion: 2024-04-08
Completion: 2024-08-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TQ05105	Small molecule	—	Oral

Indications

No indication recorded.